Georgina Long Australasian Melanoma Conference 2018

Georgina Long

Dr Georgina Long, BSc PhD MBBS FRACP, is Associate Professor of Melanoma Biology and Translational Research and Medical Oncologist at Melanoma Institute Australia, University of Sydney. She leads an extensive clinical trials team and laboratory, with a focus on targeted therapies and immuno-oncology. She has also been the principal investigator on trials using anti-PD1 compounds as monotherapy treatment or in combination with other agents. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research, Associate Professor Long was awarded the Outstanding Cancer Research Fellow 2013 at the CINSW Premier’s Awards. She is a member of the Australian Melanoma Management Guidelines Committee, the ASCO Scientific Committee, and the Melanoma Expert thPanel for AJCC Cancer Staging System 8 edition. Associate Professor Long is also on the editorial board of four journals. Associate Professor Long was educated at the University of Sydney, where she received her BSc (Hons 1) and was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Associate Professor Long became a Fellow of the Australasian College of Physicians in 2008, specialising in medical oncology. She is the author of over 110 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Journal of Clinical Oncology and Cancer Discovery. Associate Professor Long has presented her work at international conferences and meetings on more than 100 occasions.